Novartis Venture Fund

The fund's primary sourcing advantage is direct access to the global scientific community and internal R&D organization of its parent, Novartis AG. It leverages academic networks, industry conferences, and the deal flow that naturally comes to a top-tier pharmaceutical company. This internal lens allows the investment team to conduct deeper scientific due diligence on potential investments than a standalone venture firm could typically achieve.

The fund invests capital from Novartis AG's balance sheet, making it a single-LP corporate venture fund. It pursues both financial returns and strategic insight, seeking to invest in transformative therapeutics while gaining a window into emerging science. Portfolio companies are not required to enter into commercial agreements with Novartis, which preserves their optionality and the fund's ability to invest based on scientific merit.

The fund operates with a stage-agnostic mandate, investing from seed and early-stage startups through to late-stage and growth companies. Its sector focus is exclusively on life sciences, specifically biotechnology and biopharmaceutical companies developing novel therapeutics. The fund does not invest in medical devices, diagnostics, or health technology platforms, maintaining a strict focus on drug development.

Novartis Venture Fund acts as a direct equity investor capable of leading financing rounds. It builds concentrated positions in its portfolio companies, consistent with a model of taking board seats or active observer roles to provide strategic guidance. The fund's corporate backing makes it a stable, long-term partner for syndicates alongside traditional life science venture capital firms.

Investment decisions are made by the fund's dedicated internal team, which includes managing directors with deep scientific and investment backgrounds. While the team operates with a degree of independence from the parent company, its governance structure is embedded within Novartis, meaning major commitments are subject to internal approvals that reflect the strategic and financial interests of Novartis AG.